Generation Bio Co.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBIO research report →
Companygenerationbio.com
Generation Bio Co. , a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina.
- CEO
- Yalonda Howze
- IPO
- 2020
- Employees
- 115
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $35.98M
- P/E
- -0.57
- P/S
- 2.36
- P/B
- 0.71
- EV/EBITDA
- -0.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 90.81%
- Op Margin
- -553.92%
- Net Margin
- -410.13%
- ROE
- -94.82%
- ROIC
- -78.90%
Growth & Income
- Revenue
- $19.89M · 236.92%
- Net Income
- $-131,668,000 · -3.99%
- EPS
- $-19.76 · -0.66%
- Op Income
- $-142,390,000
- FCF YoY
- -51.25%
Performance & Tape
- 52W High
- $7.52
- 52W Low
- $3.00
- 50D MA
- $5.52
- 200D MA
- $5.11
- Beta
- 2.01
- Avg Volume
- 82.01K
Get TickerSpark's AI analysis on GBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Atlas Venture Fund X, L.P. | other | 60 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 6,000 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 3,000 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 5,200 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 1,500 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 1,920 |
| Feb 9, 26 | Stehman-Breen Catherine | sell | 2,500 |
| Feb 9, 26 | Stehman-Breen Catherine | other | 4,752 |
| Feb 9, 26 | Rowland Charles A Jr | sell | 1,920 |
| Feb 9, 26 | Rowland Charles A Jr | sell | 6,000 |
Our GBIO Coverage
We haven't published any research on GBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GBIO Report →